Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 25, 2000European Journal of Clinical Investigation

Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does simvastatin improve blood pressure and urinary albumin excretion independently of LDL cholesterol reduction in microalbuminuric hypertensive type 2 diabetic patients?

Population

26 microalbuminuric hypertensive type 2 diabetic patients

Comparison

Simvastatin 20 mg once daily for 10 months vs Cholestyramine 6 g three times a day for 10 months

Design

RCT, random order (cross-over)

Follow-up

10 months per treatment period

Authors

GTGiancarlo TonoloNuovo Ospedale San Giovanni di DioMMMaria Grazia MelisUniversity of SassariMFMarilena FormatoUniversity of Sassari

Discussion

Loading...

Member takes

Overview

May favor simvastatin for BP and albuminuria control in hypertensive type 2 diabetes; confirms effects independent of LDL reduction.

Key Points

  • The study aims to investigate the effects of Simvastatin on blood pressure and urinary albumin excretion in hypertensive type 2 diabetic patients, independent of its cholesterol-lowering effects.
  • Twenty-six patients with microalbuminuric hypertension received Simvastatin (20 mg/day) or Cholestyramine (6 g three times a day) over two 10-month periods with a crossover design.
  • Measurements included blood pressure, lipid levels, glycated hemoglobin, and urinary albumin excretion during the treatment periods.
  • Urinary glycosaminoglycan excretion was also measured in eight patients.
  • Simvastatin and Cholestyramine equally reduced total and LDL cholesterol levels.
  • Simvastatin treatment significantly reduced diastolic blood pressure and 24-hour urinary albumin and glycosaminoglycan excretion rates.
  • Cholestyramine did not produce significant changes in these parameters.

Structured PICO

Does simvastatin improve blood pressure and urinary albumin excretion independently of LDL cholesterol reduction in microalbuminuric hypertensive type 2 diabetic patients?

P
Population
26 microalbuminuric hypertensive type 2 diabetic patients (diastolic blood pressure > 90 and < 100 mmHg; plasma LDL-cholesterol > 3.9 and < 6.5 mmol L-1)
I
Intervention
Simvastatin 20 mg once daily for 10 months
C
Comparator
Cholestyramine 6 g three times a day for 10 months (cross-over design with 3 months wash-out)
O
Outcome
Blood pressure, lipid parameters, glycated haemoglobin and urinary albumin excretionsurrogate

Simvastatin reduces diastolic blood pressure and urinary albumin excretion in hypertensive type 2 diabetic patients independently of its LDL-lowering effects.

Cite This Study

Tonolo et al. (2000) studied this question.

synapsesocial.com/papers/6a2066b4d1cd0ea0c19cd7e1https://doi.org/10.1046/j.1365-2362.2000.00735.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.1993 · 1,133 citations
  2. 2Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide.1991 · 332 citations
  3. 3Nitric oxide availability in diabetes mellitus1998 · 191 citations
  4. 4Alterations in the Basement Membrane (Heparan Sulfate) Proteoglycan in Diabetic Mice1982 · 177 citations
  5. 5Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women1995 · 49 citations